Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the earnings conference call for the quarter and nine months ended December 31, 2022 conducted after the meeting of Board of Directors held on February 6, 2023. The above information has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-release This is for your information and record.
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our Results conference call intimation dated January 31, 2023, that audio recording of the conference call for the quarter and nine months ended December 31, 2022 held on Tuesday, February 7, 2023, has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-release This is for your information and record.
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the conference call for the investors held on December 26, 2022. The above information has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/news-events This is for your information and record.
Conference Call with Suven Pharma Management and Analysts on the acquisition of the Jasti family stake by Advent International. Listen to the transcript.
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our conference call intimation dated December 26, 2022, that audio recording of the conference call for the investors held on Monday, December 26, 2022, has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/news-events
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the earnings conference call for the quarter and half-year ended September 30, 2022 conducted after the meeting of Board of Directors held on November 8, 2022. The above information has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-release This is for your information and record.
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our Results conference call intimation dated November 3, 2022, that audio recording of the conference call for the quarter and half-year ended September 30, 2022 held on Wednesday, November 9, 2022, has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-release This is for your information and record.
